26.05.2015, 15:34
Astellas: Strategic Plan 2015-2017
OREANDA-NEWS. Astellas Pharma Inc. (“Astellas”; TSE: 4503, headquarters: Tokyo;
President and CEO Yoshihiko Hatanaka) announced a new three-year strategic plan 2015-2017
commencing from FY2015 (“this Strategic Plan”).
Summary of this Strategic Plan
As Astellas, we will strive to create solid and resilient continuity of growth over the mid- to long-term through the pursuit of three main strategies – “Maximizing Product Value”, “Creating Innovation” and “Pursuing Operational Excellence”. In recent years, our business environment has presented various challenges, such as the containment of healthcare costs by various countries’ governments, the increasing influence of the payer, more complicated approval requirements, and the shortening of the product lifecycle. Despite this, we believe there are many new opportunities available to us, as an ethical pharmaceutical business, to provide innovative value to patients through progress of science, the continued existence of areas of high unmet medical needs and the emergence of new modalities and drug-discovery technology.
Summary of this Strategic Plan
As Astellas, we will strive to create solid and resilient continuity of growth over the mid- to long-term through the pursuit of three main strategies – “Maximizing Product Value”, “Creating Innovation” and “Pursuing Operational Excellence”. In recent years, our business environment has presented various challenges, such as the containment of healthcare costs by various countries’ governments, the increasing influence of the payer, more complicated approval requirements, and the shortening of the product lifecycle. Despite this, we believe there are many new opportunities available to us, as an ethical pharmaceutical business, to provide innovative value to patients through progress of science, the continued existence of areas of high unmet medical needs and the emergence of new modalities and drug-discovery technology.
Комментарии